Key Highlights

  • Optiscan lodged a US FDA 510(k) application for its InVue precision surgery device, shortly after a 510(k) for its InForm digital pathology device on 1 October 2026.
  • The submission moves InVue into formal FDA review, and the FDA may request clarification or additional information before deciding on clearance.
  • Clearance is not assured, and the company continues work on clinical reference sites, Manufacturing scale-up and partner discussions.

Optiscan Imaging Limited (ASX:OIL) announced on 5 October 2026 the successful lodgement of a 510(k) application with the US Food and Drug Administration (FDA) for its InVue precision surgery device. It follows the 510(k) submission for the company's InForm digital pathology device announced on 1 October 2026.

What InVue is

Optiscan unveiled InVue in June 2024 as a next-generation microscopic imaging device for precision surgery. It is designed to give surgeons cellular-level imaging in the operating environment, so tissue can be assessed in real time while the patient remains in theatre. The company sees surgical oncology as the first target, across breast, head and neck, colorectal, genitourinary, skin and other tumour procedures, where surgeons must decide whether suspicious or residual tumour remains.

The FDA process

The submission brings together evidence on device performance, safety, verification and validation, risk management and clinical use, built over an extensive engineering, clinical, external testing and regulatory program. InVue now moves into formal independent review, in which the FDA may ask for clarification or more information before determining whether the device is cleared. Clinical studies will continue after submission to generate more data across surgical workflows.

Market figures cited

The company says about 60% of US cancer patients undergo surgery to treat or stage their disease, equal to about 1.27 million patients a year on 2026 incidence. It cites estimates that cancer surgery is the largest segment of the US cancer treatment facilities market, at about US$4.8 billion in annual revenue, and that the broader intraoperative imaging market is forecast to reach US$1.55 billion by 2030. These are third-party estimates and not Optiscan Revenue forecasts.

Commercial readiness

Optiscan says it is advancing commercial readiness through clinical reference sites, customer engagement, manufacturing scale-up and discussions with commercial partners, so that regulatory review and commercial preparation proceed in parallel. The release gives no expected clearance date, pricing or order information.

Regulatory and strategic significance

Optiscan describes the submission as an important regulatory inflection point that brings together performance, safety and clinical evidence into a formal application. It says clearance would provide the basis for commercial roll-out in the US for the cleared indications only. The company links the filing to its ability to turn its imaging platform into technology designed for use within the surgical workflow, though it provides no expected clearance timeframe.

Evidence and sterile-environment challenge

Optiscan notes the complexity of developing technology for use in a sterile surgical environment, where performance must be shown in the context of real-time clinical decision-making. Clinical studies have contributed to the evidence base and will continue beyond submission to build the foundation for future adoption. The company also refers to a figure showing FDA milestone progress for InVue.